Current Opinion in Lipidology was launched in 1990. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of lipidology is divided into six sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.
G. Kees Hovingh
G. Kees Hovingh (1974) received his medical degree at the University of Groningen, the Netherlands, in 2000, his PhD in 2005 and his MBA in 2016. Hovingh is an internist and vascular medicine specialist at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, the Netherlands, and visiting professor at Imperial College in London, UK. Dr Hovingh is head of the clinical trial unit and involved in a large number of clinical trials, mainly focused on novel therapies to combat (the consequences of) dyslipidemia. Dr Hovingh gained his interest in genetic lipidology via research conducted at the AMC, and he co-authored over 170 publications (Hirsh factor: 38). Through this research, Dr Hovingh has identified mutations in a large number of pivotal genes in lipid metabolism in patients with extreme dyslipidemia phenotypes. The overall aim of the unraveling of the molecular pathology in patients is to identify novel and innovative therapeutic pathways to reduce the burden of dyslipidemia and cardiovascular disease.
Jan Albert Kuivenhoven
Starting out as a molecular/cell biologist (MSc 1991 cum laude; Wageningen University, The Netherlands), Jan Albert Kuivenhoven (1964) finished his PhD at the Academic Medical Center, University of Amsterdam, the Netherlands (1996; Department of Experimental Vascular Medicine), on the genetics of high-density lipoprotein (HDL) metabolism. Following a 2.5 years post-doc at the Department of Biology, Massachusetts Institute of Biology, Boston (1997–1999), USA, where he worked on angiogenesis, he returned to Amsterdam and continued working on the genetics of human dyslipidemias. In September 2011, he moved to the University Medical Center Groningen, the Netherlands (Department of Pediatrics, Section Molecular Genetics), where he is building a basic research group with strong translational focus on identification and molecular characterization of pharmaceutical targets to treat cardiovascular disease.